Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on IQVIA Hldgs (NYSE:IQV) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 4 | 3 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 1 | 0 | 0 |
2M Ago | 0 | 0 | 1 | 0 | 0 |
3M Ago | 3 | 3 | 1 | 0 | 0 |
Analysts have recently evaluated IQVIA Hldgs and provided 12-month price targets. The average target is $234.36, accompanied by a high estimate of $286.00 and a low estimate of $202.00. This current average represents a 1.28% decrease from the previous average price target of $237.40.
The perception of IQVIA Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Luke Sergott | Barclays | Raises | Overweight | $260.00 | $215.00 |
Eric Coldwell | Baird | Raises | Neutral | $226.00 | $221.00 |
Jailendra Singh | Truist Securities | Raises | Buy | $286.00 | $240.00 |
Patrick Donnelly | Citigroup | Raises | Neutral | $225.00 | $190.00 |
Jailendra Singh | Truist Securities | Maintains | Buy | $240.00 | - |
Anne Samuel | JP Morgan | Lowers | Overweight | $239.00 | $262.00 |
Jailendra Singh | Truist Securities | Lowers | Buy | $240.00 | $260.00 |
Jack Wallace | Guggenheim | Lowers | Buy | $220.00 | $253.00 |
Tejas Savant | Morgan Stanley | Lowers | Overweight | $225.00 | $240.00 |
Luke Sergott | Barclays | Lowers | Overweight | $215.00 | $245.00 |
Eric Coldwell | Baird | Lowers | Neutral | $202.00 | $248.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into IQVIA Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on IQVIA Hldgs analyst ratings.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining IQVIA Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.88% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: IQVIA Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.25%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IQVIA Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: IQVIA Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.39, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: IQV